PMID- 36943311
OWN - NLM
STAT- MEDLINE
DCOM- 20230525
LR  - 20230525
IS  - 1479-683X (Electronic)
IS  - 0804-4643 (Linking)
VI  - 188
IP  - 5
DP  - 2023 May 10
TI  - Pancreatic imaging in MEN1-comparison of conventional and somatostatin receptor 
      positron emission tomography/computed tomography imaging in real-life setting.
PG  - 421-429
LID - 10.1093/ejendo/lvad035 [doi]
AB  - OBJECTIVE: Pancreatic neuroendocrine tumors (panNETs) are the leading cause of 
      death in patients with multiple endocrine neoplasia type 1 (MEN1). The role of 
      somatostatin receptor positron emission tomography/computed tomography (SSTR 
      PET/CT) in MEN1 has not been established. The aim was to assess pancreatic 
      imaging in MEN1 in a real-life setting. DESIGN: Fifty-eight patients with MEN1 
      [median age 40 (range 16-72) years] underwent SSTR PET/CT imaging; either as a 
      screening tool regardless of disease stage (n = 47) or to further characterize 
      known panNETs (n = 11). SSTR PET/CT and matched conventional imaging were blindly 
      analyzed. We assessed the findings and the impact of SSTR PET/CT during a median 
      follow-up of 47 months. RESULTS: SSTR PET/CT detected three times as many panNETs 
      as conventional imaging (P < .001). SSTR PET/CT altered the management of 27 
      patients (47%). Seven patients (12%) were referred for surgery, and five (9%) 
      received systemic treatment. In 15/25 (60%) patients with no previous panNET (n = 
      22) or in remission after surgery (n = 3), SSTR PET/CT identified a panNET (n = 
      14) or recurrence (n = 1). In eight patients, SSTR PET/CT revealed a panNET not 
      immediately visible on conventional imaging. During a median follow-up of 47 
      months, three became visible on conventional imaging, but none required 
      intervention. When SSTR PET/CT was negative, no panNETs were identified on 
      conventional imaging during 38 months of follow-up. CONCLUSIONS: SSTR PET/CT 
      demonstrates high accuracy in the detection of panNETs and alters the clinical 
      management in nearly half of the MEN1-patients. SSTR PET/CT enables timely 
      diagnosis and staging of MEN1-related panNETs.
CI  - (c) The Author(s) 2023. Published by Oxford University Press on behalf of European 
      Society of Endocrinology.
FAU - Kostiainen, Iiro
AU  - Kostiainen I
AUID- ORCID: 0000-0002-2358-1181
AD  - Endocrinology, Abdominal Center, Helsinki University Hospital and University of 
      Helsinki, 00029 Helsinki, Finland.
FAU - Majala, Susanna
AU  - Majala S
AD  - Department of Surgery, Division of Digestive Surgery and Urology, Turku 
      University Hospital and University of Turku, 20251 Turku, Finland.
AD  - Turku PET Centre, Turku University Hospital, 20521 Turku, Finland.
FAU - Schildt, Jukka
AU  - Schildt J
AD  - HUS Medical Imaging Center, Department of Clinical Physiology and Nuclear 
      Medicine, Helsinki University Hospital and University of Helsinki, 00029 
      Helsinki, Finland.
FAU - Parviainen, Helka
AU  - Parviainen H
AD  - HUS Medical Imaging Center, Department of Radiology, Helsinki University Hospital 
      and University of Helsinki, 00029 Helsinki, Finland.
AD  - Department of Radiology, Vaasa Central Hospital, Wellbeing Services County of 
      Ostrobothnia, 65130 Vaasa, Finland.
FAU - Kauhanen, Saila
AU  - Kauhanen S
AD  - Department of Surgery, Division of Digestive Surgery and Urology, Turku 
      University Hospital and University of Turku, 20251 Turku, Finland.
AD  - Turku PET Centre, Turku University Hospital, 20521 Turku, Finland.
FAU - Seppanen, Hanna
AU  - Seppanen H
AD  - Department of Gastrointestinal Surgery, Translational Cancer Medicine Program, 
      iCAN Digital Precision Cancer Medicine Flagship, Faculty of Medicine, Helsinki 
      University Hospital and University of Helsinki, 00029 Helsinki, Finland.
FAU - Miettinen, Paivi J
AU  - Miettinen PJ
AD  - Pediatric Research Center, New Children's Hospital, Helsinki University Hospital 
      and University of Helsinki, 00029 Helsinki, Finland.
FAU - Matikainen, Niina
AU  - Matikainen N
AD  - Endocrinology, Abdominal Center, Helsinki University Hospital and University of 
      Helsinki, 00029 Helsinki, Finland.
FAU - Ryhanen, Eeva M
AU  - Ryhanen EM
AD  - Endocrinology, Abdominal Center, Helsinki University Hospital and University of 
      Helsinki, 00029 Helsinki, Finland.
FAU - Schalin-Jantti, Camilla
AU  - Schalin-Jantti C
AD  - Endocrinology, Abdominal Center, Helsinki University Hospital and University of 
      Helsinki, 00029 Helsinki, Finland.
LA  - eng
GR  - Finska Lakaresallskapet/
GR  - TYH2020334/Helsinki University Hospital/
PT  - Journal Article
PL  - England
TA  - Eur J Endocrinol
JT  - European journal of endocrinology
JID - 9423848
RN  - 0 (Receptors, Somatostatin)
SB  - IM
CIN - Eur J Endocrinol. 2023 May 10;188(5):C9-C10. PMID: 37220756
MH  - Humans
MH  - Adolescent
MH  - Young Adult
MH  - Adult
MH  - Middle Aged
MH  - Aged
MH  - Positron Emission Tomography Computed Tomography/methods
MH  - *Multiple Endocrine Neoplasia Type 1
MH  - Receptors, Somatostatin
MH  - *Pancreatic Neoplasms/diagnosis
MH  - Pancreas/pathology
MH  - *Neuroendocrine Tumors/pathology
OTO - NOTNLM
OT  - MEN1
OT  - NET
OT  - pancreas
OT  - pancreatic neuroendocrine tumor
OT  - somatostatin receptor PET/CT
COIS- Conflicts of interest: None declared.
EDAT- 2023/03/22 06:00
MHDA- 2023/05/25 06:42
CRDT- 2023/03/21 11:43
PHST- 2023/02/03 00:00 [received]
PHST- 2023/03/02 00:00 [revised]
PHST- 2023/03/13 00:00 [accepted]
PHST- 2023/05/25 06:42 [medline]
PHST- 2023/03/22 06:00 [pubmed]
PHST- 2023/03/21 11:43 [entrez]
AID - 7082472 [pii]
AID - 10.1093/ejendo/lvad035 [doi]
PST - ppublish
SO  - Eur J Endocrinol. 2023 May 10;188(5):421-429. doi: 10.1093/ejendo/lvad035.